{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T13:37:27Z","timestamp":1772199447172,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","funder":[{"DOI":"10.13039\/100013501","name":"INCA","doi-asserted-by":"crossref","award":["2014-132, R14208KK"],"award-info":[{"award-number":["2014-132, R14208KK"]}],"id":[{"id":"10.13039\/100013501","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1186\/s12874-016-0166-7","type":"journal-article","created":{"date-parts":[[2016,6,2]],"date-time":"2016-06-02T04:11:09Z","timestamp":1464840669000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of a multi-arm multi-stage Bayesian design for phase II drug selection trials \u2013 an example in hemato-oncology"],"prefix":"10.1186","volume":"16","author":[{"given":"Louis","family":"Jacob","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Uvarova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandrine","family":"Boulet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inva","family":"Begaj","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sylvie","family":"Chevret","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,6,2]]},"reference":[{"key":"166_CR1","doi-asserted-by":"crossref","first-page":"206","DOI":"10.7326\/0003-4819-151-3-200908040-00126","volume":"151","author":"BR Luce","year":"2009","unstructured":"Luce BR, Kramer JM, Goodman SN, Connor JT, Tunis S, Whicher D, Schwartz JS. Rethinking randomized clinical trials for comparative effectiveness research: the need for transformational change. Ann Intern Med. 2009;151:206\u20139. PMID: 19567619.","journal-title":"Ann Intern Med"},{"key":"166_CR2","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1200\/JCO.2011.38.5732","volume":"30","author":"EL Korn","year":"2012","unstructured":"Korn EL, Freidlin B, Abrams JS, Halabi S. Design issues in randomized phase II\/III trials. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:667\u201371. doi: 10.1200\/JCO.2011.38.5732 [PMID: 22271475PMCID: PMC3295562].","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"166_CR3","doi-asserted-by":"publisher","first-page":"7199","DOI":"10.1200\/JCO.2005.01.149","volume":"23","author":"LV Rubinstein","year":"2005","unstructured":"Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol Off J Am Soc Clin Oncol. 2005;23:7199\u2013206. doi: 10.1200\/JCO.2005.01.149 . PMID: 16192604.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"166_CR4","doi-asserted-by":"crossref","first-page":"S158","DOI":"10.1016\/S0002-8703(00)90064-4","volume":"139","author":"SS Ellenberg","year":"2000","unstructured":"Ellenberg SS. Select-drop designs in clinical trials. Am Heart J. 2000;139:S158\u2013160. PMID: 10740123.","journal-title":"Am Heart J"},{"key":"166_CR5","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1158\/1078-0432.CCR-08-0325","volume":"14","author":"B Freidlin","year":"2008","unstructured":"Freidlin B, Korn EL, Gray R, Martin A. Multi-arm clinical trials of new agents: some design considerations. Clin Cancer Res Off J Am Assoc Cancer Res. 2008;14:4368\u201371. doi: 10.1158\/1078-0432.CCR-08-0325 . PMID: 18628449.","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc Cancer Res"},{"key":"166_CR6","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/1471-2288-13-139","volume":"13","author":"DJ Bratton","year":"2013","unstructured":"Bratton DJ, Phillips PPJ, Parmar MKB. A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosis. BMC Med Res Methodol. 2013;13:139. doi: 10.1186\/1471-2288-13-139 [PMID: 24229079PMCID: PMC3840569].","journal-title":"BMC Med Res Methodol"},{"key":"166_CR7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1080\/10543400902802425","volume":"19","author":"YK Cheung","year":"2009","unstructured":"Cheung YK. Selecting promising treatments in randomized phase II cancer trials with an active control. J Biopharm Stat. 2009;19:494\u2013508. doi: 10.1080\/10543400902802425 [PMID: 19384691PMCID: PMC2896482].","journal-title":"J Biopharm Stat"},{"key":"166_CR8","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1745-6215-12-81","volume":"12","author":"P Royston","year":"2011","unstructured":"Royston P, Barthel FM-S, Parmar MK, Choodari-Oskooei B, Isham V. Designs for clinical trials with time-to-event outcomes based on stopping guidelines for lack of benefit. Trials. 2011;12:81. doi: 10.1186\/1745-6215-12-81 [PMID: 21418571PMCID: PMC3078872].","journal-title":"Trials"},{"key":"166_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/nrd1927","volume":"5","author":"DA Berry","year":"2006","unstructured":"Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27\u201336. doi: 10.1038\/nrd1927 . PMID: 16485344.","journal-title":"Nat Rev Drug Discov"},{"key":"166_CR10","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1002\/sim.5404","volume":"31","author":"JJ Lee","year":"2012","unstructured":"Lee JJ, Chu CT. Bayesian clinical trials in action. Stat Med. 2012;31:2955\u201372. doi: 10.1002\/sim.5404 [PMID: 22711340PMCID: PMC3495977].","journal-title":"Stat Med"},{"issue":"12","key":"166_CR11","doi-asserted-by":"publisher","first-page":"2048","DOI":"10.1002\/sim.6469","volume":"34","author":"J Whitehead","year":"2015","unstructured":"Whitehead J, Cleary F, Turner A. Bayesian sample sizes for exploratory clinical trials comparing multiple experimental treatments with a control. Stat Med. 2015;34(12):2048\u201361. doi: 10.1002\/sim.6469 . PMID: 25765252.","journal-title":"Stat Med"},{"issue":"1","key":"166_CR12","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/j.1541-0420.2012","volume":"69","author":"BG Zalavsky","year":"2013","unstructured":"Zalavsky BG. Bayesian hypothesis testing in two-arm trials with dichotomous outcomes. Biometrics. 2013;69(1):157\u201363. doi: 10.1111\/j.1541-0420.2012 .","journal-title":"Biometrics"},{"key":"166_CR13","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.cct.2012.03.001","volume":"33","author":"F Xie","year":"2012","unstructured":"Xie F, Ji Y, Tremmel L. A Bayesian adaptive design for multi-dose, randomized, placebo-controlled phase I\/II trials. Contemp Clin Trials. 2012;33:739\u201348. doi: 10.1016\/j.cct.2012.03.001 . PMID: 22426247.","journal-title":"Contemp Clin Trials"},{"key":"166_CR14","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/sim.2961","volume":"27","author":"S-H Jung","year":"2008","unstructured":"Jung S-H. Randomized phase II trials with a prospective control. Stat Med. 2008;27:568\u201383. doi: 10.1002\/sim.2961 . PMID: 17573688.","journal-title":"Stat Med"},{"key":"166_CR15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2307\/2533377","volume":"50","author":"PF Thall","year":"1994","unstructured":"Thall PF, Simon R. Practical Bayesian guidelines for phase IIB clinical trials. Biometrics. 1994;50:337\u201349. PMID: 7980801.","journal-title":"Biometrics"},{"key":"166_CR16","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1177\/1740774510373120","volume":"7","author":"JJ Lee","year":"2010","unstructured":"Lee JJ, Xuemin Gu N, Suyu Liu N. Bayesian adaptive randomization designs for targeted agent development. Clin Trials Lond Engl. 2010;7:584\u201396. doi: 10.1177\/1740774510373120 . PMID: 20571130.","journal-title":"Clin Trials Lond Engl"},{"key":"166_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.cct.2014.11.006","volume":"40","author":"Y Du","year":"2015","unstructured":"Du Y, Wang X, Jack Lee J. Simulation study for evaluating the performance of response-adaptive randomization. Contemp Clin Trials. 2015;40:15\u201325. doi: 10.1016\/j.cct.2014.11.006 [PMID: 25460340PMCID: PMC4314433].","journal-title":"Contemp Clin Trials"},{"key":"166_CR18","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1080\/03610929308831114","volume":"22","author":"T Pham-Gia","year":"1993","unstructured":"Pham-Gia T, Turkkan N, Eng P. Bayesian analysis of the difference of two proportions. Commun Stat Theory Methods. 1993;22:1755\u201371. doi: 10.1080\/03610929308831114 .","journal-title":"Commun Stat Theory Methods"},{"key":"166_CR19","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1080\/10543406.2010.544438","volume":"22","author":"Y Kawasaki","year":"2012","unstructured":"Kawasaki Y, Miyaoka E. A Bayesian inference of P(\u03c01 > \u03c02) for two proportions. J Biopharm Stat. 2012;22:425\u201337. doi: 10.1080\/10543406.2010.544438 [00005 PMID: 22416833].","journal-title":"J Biopharm Stat"},{"key":"166_CR20","unstructured":"Cook J: Exact Calculation of Beta Inequalities. Tech. Rep. 2005, http:\/\/www.johndcook.com\/exact_probability_inequalitiy.pdf"},{"key":"166_CR21","doi-asserted-by":"publisher","unstructured":"Morita S, Thall PF, M\u00fcller P: Evaluating the Impact of Prior Assumptions in Bayesian Biostatistics. Stat. Biosci. 2010, 2:1\u201317. [doi: 10.1007\/s12561-010-9018-x ] [PMID: 20668651PMCID: PMC2910452].","DOI":"10.1007\/s12561-010-9018-x"},{"key":"166_CR22","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1177\/1740774513493528","volume":"10","author":"M Moatti","year":"2013","unstructured":"Moatti M, Zohar S, Facon T, Moreau P, Mary J-Y, Chevret S. Modeling of experts\u2019 divergent prior beliefs for a sequential phase III clinical trial. Clin Trials Lond Engl. 2013;10:505\u201314. doi: 10.1177\/1740774513493528 . PMID: 23820061.","journal-title":"Clin Trials Lond Engl"},{"key":"166_CR23","first-page":"1","volume":"4","author":"DJ Spiegelhalter","year":"2000","unstructured":"Spiegelhalter DJ, Myles JP, Jones DR, Abrams KR. Bayesian methods in health technology assessment: a review. Health Technol Assess Winch Engl. 2000;4:1\u2013130. PMID: 11134920.","journal-title":"Health Technol Assess Winch Engl"},{"key":"166_CR24","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/1740774506070654","volume":"3","author":"JMG Taylor","year":"2006","unstructured":"Taylor JMG, Braun TM, Li Z. Comparing an experimental agent to a standard agent: relative merits of a one-arm or randomized two-arm Phase II design. Clin Trials Lond Engl. 2006;3:335\u201348. doi: 10.1177\/1740774506070654 . PMID: 17060208.","journal-title":"Clin Trials Lond Engl"},{"key":"166_CR25","doi-asserted-by":"publisher","unstructured":"Ratain MJ, Sargent DJ. Optimising the design of phase II oncology trials: the importance of randomisation. Eur. J. Cancer Oxf. Engl. 1990 2009, 45:275\u2013280. [doi: 10.1016\/j.ejca.2008.10.029 ] [PMID: 19059773].","DOI":"10.1016\/j.ejca.2008.10.029"},{"key":"166_CR26","doi-asserted-by":"publisher","unstructured":"Baron G, Perrodeau E, Boutron I, Ravaud P. Reporting of analyses from randomized controlled trials with multiple arms: a systematic review. BMC Med. 2013, 11:84. [doi: 10.1186\/1741-7015-11-84 ] [PMID: 23531230PMCID: PMC3621416].","DOI":"10.1186\/1741-7015-11-84"},{"key":"166_CR27","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1002\/sim.6086","volume":"33","author":"JMS Wason","year":"2014","unstructured":"Wason JMS, Trippa L. A comparison of Bayesian adaptive randomization and multi-stage designs for multi-arm clinical trials. Stat Med. 2014;33:2206\u201321. doi: 10.1002\/sim.6086 . PMID: 24421053.","journal-title":"Stat Med"},{"key":"166_CR28","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1002\/sim.5513","volume":"31","author":"JMS Wason","year":"2012","unstructured":"Wason JMS, Jaki T. Optimal design of multi-arm multi-stage trials. Stat Med. 2012;31:4269\u201379. doi: 10.1002\/sim.5513 . PMID: 22826199.","journal-title":"Stat Med"},{"key":"166_CR29","doi-asserted-by":"publisher","unstructured":"Cai C, Yuan Y, Johnson VE. Bayesian adaptive phase II screening design for combination trials. Clin. Trials Lond. Engl. 2013, 10:353\u2013362. [doi: 10.1177\/1740774512470316 ] [PMID: 23359875PMCID: PMC3867529].","DOI":"10.1177\/1740774512470316"},{"key":"166_CR30","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1111\/j.1541-0420.2006.00685.x","volume":"63","author":"X Huang","year":"2007","unstructured":"Huang X, Biswas S, Oki Y, Issa J-P, Berry DA. A parallel phase I\/II clinical trial design for combination therapies. Biometrics. 2007;63:429\u201336. doi: 10.1111\/j.1541-0420.2006.00685.x . PMID: 17688495.","journal-title":"Biometrics"},{"key":"166_CR31","doi-asserted-by":"publisher","unstructured":"Pan H, Xie F, Liu P, Xia J, Ji Y. A phase I\/II seamless dose escalation\/expansion with adaptive randomization scheme (SEARS). Clin. Trials Lond. Engl. 2014, 11:49\u201359. [doi: 10.1177\/1740774513500081 ] [PMID: 24137041PMCID: PMC4281526].","DOI":"10.1177\/1740774513500081"},{"key":"166_CR32","doi-asserted-by":"publisher","unstructured":"Freidlin B, Korn EL. Monitoring for lack of benefit: a critical component of a randomized clinical trial. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2009, 27:629\u2013633. [doi: 10.1200\/JCO.2008.17.8905 ] [PMID: 19064977PMCID: PMC2645857].","DOI":"10.1200\/JCO.2008.17.8905"},{"key":"166_CR33","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1002\/sim.3559","volume":"28","author":"W Brannath","year":"2009","unstructured":"Brannath W, Zuber E, Branson M, Bretz F, Gallo P, Posch M, Racine-Poon A. Confirmatory adaptive designs with Bayesian decision tools for a targeted therapy in oncology. Stat Med. 2009;28:1445\u201363. doi: 10.1002\/sim.3559 .","journal-title":"Stat Med"},{"issue":"11\u201312","key":"166_CR34","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1002\/sim.4363","volume":"31","author":"S Chevret","year":"2012","unstructured":"Chevret S. Bayesian adaptive clinical trials: a dream for statisticians only? Stat Med. 2012;31(11\u201312):1002\u201313. doi: 10.1002\/sim.4363 . PMID:21905067.","journal-title":"Stat Med"},{"key":"166_CR35","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ahj.2011.11.023","volume":"164","author":"SP Collins","year":"2012","unstructured":"Collins SP, Lindsell CJ, Pang PS, Storrow AB, Peacock WF, Levy P, Rahbar MH, Del Junco D, Gheorghiade M, Berry DA. Bayesian adaptive trial design in acute heart failure syndromes: moving beyond the mega trial. Am Heart J. 2012;164:138\u201345. doi: 10.1016\/j.ahj.2011.11.023 [PMID: 22877798PMCID: PMC3417230].","journal-title":"Am Heart J"},{"key":"166_CR36","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.cct.2013.09.009","volume":"36","author":"X Gu","year":"2013","unstructured":"Gu X, Yin G, Lee JJ. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints. Contemp Clin Trials. 2013;36:642\u201350. doi: 10.1016\/j.cct.2013.09.009 [PMID: 24075829PMCID: PMC3873734].","journal-title":"Contemp Clin Trials"},{"key":"166_CR37","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.cct.2014.09.001","volume":"39","author":"TL Lai","year":"2014","unstructured":"Lai TL, Lavori PW, Liao OY-W. Adaptive choice of patient subgroup for comparing two treatments. Contemp Clin Trials. 2014;39:191\u2013200. doi: 10.1016\/j.cct.2014.09.001 . PMID: 25205644.","journal-title":"Contemp Clin Trials"},{"key":"166_CR38","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.cct.2015.03.001","volume":"42","author":"Z Gao","year":"2015","unstructured":"Gao Z, Roy A, Tan M. Multistage adaptive biomarker-directed targeted design for randomized clinical trials. Contemp Clin Trials. 2015;42:119\u201331. doi: 10.1016\/j.cct.2015.03.001 . PMID: 25778672.","journal-title":"Contemp Clin Trials"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-016-0166-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:28:08Z","timestamp":1589668088000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-016-0166-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6,2]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["166"],"URL":"https:\/\/doi.org\/10.1186\/s12874-016-0166-7","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,6,2]]},"article-number":"67"}}